KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

CRISPR Therapeutics AG (CRSP) EBITDA (2016 - 2025)

Historic EBITDA for CRISPR Therapeutics AG (CRSP) over the last 11 years, with Q3 2025 value amounting to -$105.5 million.

  • CRISPR Therapeutics AG's EBITDA fell 4551.57% to -$105.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$493.9 million, marking a year-over-year decrease of 12223.44%. This contributed to the annual value of -$366.3 million for FY2024, which is 16925.76% down from last year.
  • CRISPR Therapeutics AG's EBITDA amounted to -$105.5 million in Q3 2025, which was down 4551.57% from -$208.6 million recorded in Q2 2025.
  • CRISPR Therapeutics AG's EBITDA's 5-year high stood at $759.1 million during Q2 2021, with a 5-year trough of -$208.6 million in Q2 2025.
  • Over the past 5 years, CRISPR Therapeutics AG's median EBITDA value was -$113.5 million (recorded in 2021), while the average stood at -$65.2 million.
  • As far as peak fluctuations go, CRISPR Therapeutics AG's EBITDA skyrocketed by 105288.29% in 2021, and later plummeted by 15649.7% in 2024.
  • Quarter analysis of 5 years shows CRISPR Therapeutics AG's EBITDA stood at -$145.5 million in 2021, then rose by 28.57% to -$104.0 million in 2022, then soared by 194.32% to $98.1 million in 2023, then plummeted by 146.95% to -$46.0 million in 2024, then tumbled by 129.16% to -$105.5 million in 2025.
  • Its last three reported values are -$105.5 million in Q3 2025, -$208.6 million for Q2 2025, and -$133.7 million during Q1 2025.